Swedish Orphan International
 
 
HOME ABOUT US THERAPY AREAS AND PRODUCTS PATIENTS PARTNERS MEDIA & INVESTOR CONTACT
Goals, mission and background Business Strategy CEO'S STATEMENT History 8 year overview Press releases News Financial Reports Image gallery Calendar Presentations Corporate Governance
Home / Media & Investor / News

NEWS

  • 2008
  • 5/15/2008

    Regional research still hampered by cross-border differences

    Some of these companies may be developin...

  • 4/22/2008

    Pharmamar Initiates A Phase II Study Of Yondelis In Children With Recurrent Soft Tissue Sarcomas

    Pharmamar Initiates A Phase II Study Of ...

  • 2/22/2008

    Eus COMP announces positive opinion on nine orphan drugs

    Eus COMP announces positive opinion on n...

  • 2/20/2008

    Interferon-alfa kan förbättra prognosen vid högriskmelanom

    J Interferon Cytokine Res. 1997;17:103-5...

  • 2/20/2008

    Cancer patient travels to Denmark

    Richard Ramsey, from Stanley Road, East ...

  • 1/3/2008

    Growth Of Self-administration Challenging Drug Delivery - Greystone Associates Examines Key Technology And Commercialization Factors

    Nowhere is this more evident than in the...

  • 1/2/2008

    New partnership agreement for developing drugs for patients with rare diseases

    Read the article from CheckBiotech

  • 1/2/2008

    Innovex Promotes Yondelis Cancer Treatment

    Read the article from eMaxHealth

  • 1/2/2008

    Multiple Sclerosis Progress May Be Slowed With Antibiotics

    Read the article from Medical News Today

IR & MEDIA CONTACT

Telephone +46 8 412 98 00
ir.media@swedishorphan.com

Swedish Orphan International  Drottninggatan 98   SE-111 60 Stockholm   Telephone +46 8 412 98 00   Fax +46 8 412 98 99   info@swedishorphan.com   Terms of use